Targeting YAP in pancreatic ductal adenocarcinoma (PDAC) (Homo sapiens)
From WikiPathways
Description
"Targeting YAP for PDAC therapy. There are several strategies for targeting YAP in PDAC. Statin-mediated inhibition of HMG-CoA reductase in the mevalonate pathway reduces the geranylgeranylation and membrane localization of Rho GTPases, restricting YAP nuclear accumulation and thus its activity. Verteporfin and VGLL4-mimicking peptides disrupt the interaction between YAP and TEAD, inhibiting YAP-induced transcription. Metformin activates AMPK, which inhibits YAP both directly and by activating LATS kinases. BET inhibitors oppose the transcription of YAP-regulated genes. Neratinib increases the phosphorylation of LATS1 and YAP, causing YAP cytosolic accumulation and degradation." Based on Figure F5 in https://pubmed.ncbi.nlm.nih.gov/33408779/. Derived from PFOCR, https://pfocr.wikipathways.org/figures/PMC7778590__thnov11p1753g005.html.
Please use the New WikiPathways
View approved pathways at the new wikipathways.org. This website will shutdown soon.Quality Tags
Ontology Terms
Saving...Bibliography
- Mao W, Mai J, Peng H, Wan J, Sun T; ''YAP in pancreatic cancer: oncogenic role and therapeutic strategy.''; Theranostics, 2021 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
| View all... |
| Name | Type | Database reference | Comment |
|---|---|---|---|
| Atorvastatin | Metabolite | ||
| CCN1 | GeneProduct | ENSG00000142871 (Ensembl)  | |
| CCN2 | GeneProduct | ENSG00000118523 (Ensembl) | |
| Fluvastatin | Metabolite | ||
| HMG-CoA | Metabolite | ||
| HMGCR | GeneProduct | ENSG00000113161 (Ensembl) | "HMG-CoA reductase" originally |
| JQ1 | Metabolite | ||
| LATS1 | GeneProduct | ENSG00000131023 (Ensembl) | |
| LATS2 | GeneProduct | ENSG00000150457 (Ensembl) | |
| Lovastatin | Metabolite | ||
| MOB1A | GeneProduct | ENSG00000114978 (Ensembl) | |
| Metformin | Metabolite | ||
| Mevalonic acid | Metabolite | ||
| Neratinib | Metabolite | ||
| PRKAA1 | GeneProduct | ENSG00000132356 (Ensembl) | |
| PRKAA2 | GeneProduct | ENSG00000162409 (Ensembl) | |
| PRKAB1 | GeneProduct | ENSG00000111725 (Ensembl) | |
| PRKAB2 | GeneProduct | ENSG00000131791 (Ensembl) | |
| PRKAG1 | GeneProduct | ENSG00000181929 (Ensembl) | |
| PRKAG2 | GeneProduct | ENSG00000106617 (Ensembl) | |
| PRKAG3 | GeneProduct | ENSG00000115592 (Ensembl) | |
| Pitavastatin | Metabolite | ||
| Pravastatin | Metabolite | ||
| RHOA | GeneProduct | ENSG00000067560 (Ensembl) | |
| RHOB | GeneProduct | ENSG00000143878 (Ensembl) | |
| RHOC | GeneProduct | ENSG00000155366 (Ensembl) | |
| RHOD | GeneProduct | ENSG00000173156 (Ensembl) | |
| RHO | GeneProduct | ENSG00000163914 (Ensembl) | |
| Rosuvastatin | Metabolite | ||
| SAV1 | GeneProduct | ENSG00000151748 (Ensembl) | |
| STK3 | GeneProduct | ENSG00000104375 (Ensembl) | |
| STK4 | GeneProduct | ENSG00000101109 (Ensembl) | |
| Simvastatin | Metabolite | ||
| TEAD1 | GeneProduct | ENSG00000187079 (Ensembl) | |
| TEAD2 | GeneProduct | ENSG00000074219 (Ensembl) | |
| TEAD3 | GeneProduct | ENSG00000007866 (Ensembl) | |
| TEAD4 | GeneProduct | ENSG00000197905 (Ensembl) | |
| VGLL4-mimicking peptides | Metabolite | ||
| Verteporfin | Metabolite | ||
| YAP1 | GeneProduct | ENSG00000137693 (Ensembl) |
Annotated Interactions
No annotated interactions
